Intravenously infused synthetic 500 nm nanoparticles composed of poly(lactide-co-glycolide) are taken up by blood-borne inflammatory monocytes via a macrophage scavenger receptor (macrophage receptor with collagenous structure), and the monocytes no longer traffic to sites of inflammation. Intravenous administration of the nanoparticles after experimental spinal cord injury in mice safely and selectively limited infiltration of hematogenous monocytes into the injury site. The nanoparticles did not bind to resident microglia, and did not change the number of microglia in the injured spinal cord. Nanoparticle administration reduced M1 macrophage polarization and microglia activation, reduced levels of inflammatory cytokines, and markedly reduced fibrotic scar formation without altering glial scarring. These findings thus implicate early-infiltrating hematogenous monocytes as highly selective contributors to fibrosis that do not play an indispensable role in gliosis after SCI. Further, the nanoparticle treatment reduced accumulation of chondroitin sulfate proteoglycans, increased axon density inside and caudal to the lesion site, and significantly improved functional recovery after both moderate and severe injuries to the spinal cord. These data provide further evidence that hematogenous monocytes contribute to inflammatory damage and fibrotic scar formation after spinal cord injury in mice. Further, since the nanoparticles are simple to administer intravenously, immunologically inert, stable at room temperature, composed of an FDAapproved material, and have no known toxicity, these findings suggest that the nanoparticles potentially offer a practical treatment for human spinal cord injury.
Introduction
Traumatic injury to the spinal cord (SCI) disrupts the blood-brain barrier and leads to a cascade of secondary responses including a rapid influx of monocytes into the injured area. Monocyte infiltration occurs in a biphasic pattern (Berton and Lowell, 1999; Boros et al., 2010; Shantsila et al., 2011) that begins within hours after SCI. The number of macrophages peaks at 7 days with a second peak at 14-28 days post injury. Infiltrating monocytes, as well as tissue resident microglia, differentiate into macrophages (Fleming et al., 2006; Beck et al., 2010; David and Kroner, 2011) . Monocytes and macrophages/microglia in the injured spinal cord have both detrimental and beneficial actions, and the exact roles of these populations after SCI are yet to be fully elucidated (Meda et al., 1995; Popovich et al., 1999; Popovich et al., 2002; Majed et al., 2006; Letellier et al., 2010) . Recent studies suggest that the early influx of hematogenously-derived macrophages (hMΦ), but not macrophages derived from resident microglia (mMΦ), is primarily responsible for secondary axonal dieback after SCI (Beck et al., 2010; Durafourt et al., 2012; Evans et al., 2014; Gensel and Zhang, 2015) . Thus, selectively blocking hMΦ infiltration during the early phase of SCI without altering microglia could help limit secondary tissue damage while preserving the beneficial effects of mMΦ.
The tools used in prior studies of monocyte/macrophage depletion do not exclusively target only hMΦ. Clodronate liposomes, when injected intravenously, deplete circulating monocytes and improve motor functions after SCI in rodents (Popovich et al., 1999; Horn et al., 2008; Grosso et al., 2014) . However, clodronate liposomes also target and destroy CNS resident microglia (Kumamaru et al., 2012; Plemel et al., 2014) , which may reduce the beneficial effects exerted by microglia in the damaged spinal cord. CCR2 antagonists (Kang et al., 2011) , and CCR2 small interfering RNA (Leuschner et al., 2011) target hematogenous monocytes and may spare microglia which do not express CCR2 (Jung et al., 2009; Mizutani et al., 2012) . However, this approach also targets T cells and immature B Neurobiology of Disease 108 (2017) 73-82 
